| Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC (NCT07750704) | Guangdong Association of Clinical Trials | 2026-09-01 |
| A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression (NCT07412262) | Guangdong Association of Clinical Trials | 2026-05-15 |
| PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC (NCT07416058) | Guangdong Association of Clinical Trials | 2026-01-31 |
| A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy (NCT07375316) | Guangdong Association of Clinical Trials | 2025-12-15 |
| Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) (NCT07120698) | Guangdong Association of Clinical Trials | 2025-11-05 |
| IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation (NCT07198841) | Guangdong Association of Clinical Trials | 2025-11-03 |
| RGL-270 + ICI in Advanced NSCLC (NCT07652125) | Guangdong Association of Clinical Trials | 2025-10-25 |
| A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China (NCT07198620) | Guangdong Association of Clinical Trials | 2025-10-01 |
| QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC (NCT07134413) | Guangdong Association of Clinical Trials | 2025-08-01 |
| Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma (NCT06858410) | Guangdong Association of Clinical Trials | 2025-03-01 |
| Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC (NCT06709274) | Guangdong Association of Clinical Trials | 2024-11-01 |
| Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases (NCT06282874) | Guangdong Association of Clinical Trials | 2024-08-01 |
| Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC (NCT06092086) | Guangdong Association of Clinical Trials | 2023-08-18 |
| Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment (NCT05957510) | Guangdong Association of Clinical Trials | 2023-07-07 |
| Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC (NCT05536505) | Guangdong Association of Clinical Trials | 2022-09-13 |
| Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD (NCT05457049) | Guangdong Association of Clinical Trials | 2022-08-01 |
| MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) (NCT04841811) | Guangdong Association of Clinical Trials | 2022-06-20 |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC (NCT05163249) | Guangdong Association of Clinical Trials | 2022-05-31 |
| Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC (NCT04988607) | Guangdong Association of Clinical Trials | 2021-08-01 |
| Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC (NCT04768075) | Guangdong Association of Clinical Trials | 2021-05-28 |
| Efficacy and Safety of Camrelizumab in Real-World Prospective Study (NCT04793139) | Guangdong Association of Clinical Trials | 2021-04-01 |
| Efficacy and Safety of Camrelizumab in Real-World Study (NCT04631146) | Guangdong Association of Clinical Trials | 2020-11-30 |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study (NCT04575415) | Guangdong Association of Clinical Trials | 2020-10-07 |
| An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases (NCT04339829) | Guangdong Association of Clinical Trials | 2020-08-01 |
| Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy (NCT03046316) | Guangdong Association of Clinical Trials | 2020-06-01 |
| A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy (NCT04306042) | Guangdong Association of Clinical Trials | 2020-03-01 |
| Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer (NCT04252365) | Guangdong Association of Clinical Trials | 2020-03-01 |
| A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China (NCT04015778) | Guangdong Association of Clinical Trials | 2019-08-08 |
| Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI (NCT04007835) | Guangdong Association of Clinical Trials | 2019-07-01 |
| The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China (NCT04286841) | Guangdong Association of Clinical Trials | 2019-05-01 |
| Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC (NCT03768037) | Guangdong Association of Clinical Trials | 2018-11-26 |
| A Non-interventional Retrospective Study on Overall Survival in Completely Resected Chinese NSCLC Patients With Adenocarcinoma Histology- ICAN Extension Study (NCT03658928) | Guangdong Association of Clinical Trials | 2018-08-31 |
| A Real World Study Based on NGS (TRUMPRWS) (NCT03605602) | Guangdong Association of Clinical Trials | 2018-08-01 |
| The Impact of Neurocognitive Function in Patients With Multiple Brain Metastases Receiving Whole Brain Radiation Therapy (NCT03626818) | Guangdong Association of Clinical Trials | 2018-08-01 |
| Phase II Umbrella Study Directed by Next Generation Sequencing (NCT03574402) | Guangdong Association of Clinical Trials | 2018-07-09 |